BiodesixBDSX
About: Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Employees: 273
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
3,393% more call options, than puts
Call options by funds: $524K | Put options by funds: $15K
214% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 7
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
13% more funds holding
Funds holding: 52 [Q3] → 59 (+7) [Q4]
2.53% less ownership
Funds ownership: 42.86% [Q3] → 40.33% (-2.53%) [Q4]
19% less capital invested
Capital invested by funds: $111M [Q3] → $89.7M (-$21.2M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for BDSX.
Financial journalist opinion
Based on 5 articles about BDSX published over the past 30 days
